Cargando…

The impact of the COVID‐19 pandemic on melanoma diagnoses

INTRODUCTION: We investigated whether governmental measures and lockdowns during the COVID‐19 pandemic had an impact on the number and histopathologic stages of melanoma. METHODS: The number and thickness (Breslow) of all diagnosed melanomas per day, month, or period at the ‘Institute for Pathology...

Descripción completa

Detalles Bibliográficos
Autores principales: Weltler, Patrick, Rappersberger, Klemens, Filzmoser, Peter, Vujic, Igor
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9088572/
https://www.ncbi.nlm.nih.gov/pubmed/37829553
http://dx.doi.org/10.1002/jvc2.15
_version_ 1784704355097640960
author Weltler, Patrick
Rappersberger, Klemens
Filzmoser, Peter
Vujic, Igor
author_facet Weltler, Patrick
Rappersberger, Klemens
Filzmoser, Peter
Vujic, Igor
author_sort Weltler, Patrick
collection PubMed
description INTRODUCTION: We investigated whether governmental measures and lockdowns during the COVID‐19 pandemic had an impact on the number and histopathologic stages of melanoma. METHODS: The number and thickness (Breslow) of all diagnosed melanomas per day, month, or period at the ‘Institute for Pathology in the Centre’ in 2019 and 2020 were compared. For 2020, we defined four time periods: Period 1: 1 January–15 March; Period 2: 16 March–15 May (Lockdown 1); Period 3: 16 May–2 November; Period 4: 3 November–7 December (Lockdown 2). RESULTS: We found similar melanoma numbers in 2019 (577) and 2020 (608). The mean number of diagnoses per day during Lockdown 1 (Period 2) was significantly lower (0.87 melanomas/day; p = 0.005) when compared to the respective time periods in 2019 and to the other three periods in 2020 (Period 1: 1.65 melanomas/day, Period 3: 1.77 melanomas/day, and Period 4: 2.49 melanomas/day). Tumour thickness in July 2020 (1.9 mm) was significantly higher (p = 0.02) than in July 2019 (1.1 mm). DISCUSSION: The significant lower number of histopathologic diagnoses of melanoma during ‘Lockdown 1’ may be explained by postponed or missed patient consultations. This assumption is supported by the demonstration of a higher tumour thickness in July and August 2020, compared to 2019.
format Online
Article
Text
id pubmed-9088572
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-90885722022-05-10 The impact of the COVID‐19 pandemic on melanoma diagnoses Weltler, Patrick Rappersberger, Klemens Filzmoser, Peter Vujic, Igor JEADV Clinical Practice Short Reports INTRODUCTION: We investigated whether governmental measures and lockdowns during the COVID‐19 pandemic had an impact on the number and histopathologic stages of melanoma. METHODS: The number and thickness (Breslow) of all diagnosed melanomas per day, month, or period at the ‘Institute for Pathology in the Centre’ in 2019 and 2020 were compared. For 2020, we defined four time periods: Period 1: 1 January–15 March; Period 2: 16 March–15 May (Lockdown 1); Period 3: 16 May–2 November; Period 4: 3 November–7 December (Lockdown 2). RESULTS: We found similar melanoma numbers in 2019 (577) and 2020 (608). The mean number of diagnoses per day during Lockdown 1 (Period 2) was significantly lower (0.87 melanomas/day; p = 0.005) when compared to the respective time periods in 2019 and to the other three periods in 2020 (Period 1: 1.65 melanomas/day, Period 3: 1.77 melanomas/day, and Period 4: 2.49 melanomas/day). Tumour thickness in July 2020 (1.9 mm) was significantly higher (p = 0.02) than in July 2019 (1.1 mm). DISCUSSION: The significant lower number of histopathologic diagnoses of melanoma during ‘Lockdown 1’ may be explained by postponed or missed patient consultations. This assumption is supported by the demonstration of a higher tumour thickness in July and August 2020, compared to 2019. John Wiley and Sons Inc. 2022-03-13 2022-06 /pmc/articles/PMC9088572/ /pubmed/37829553 http://dx.doi.org/10.1002/jvc2.15 Text en © 2022 The Authors. JEADV Clinical Practice published by John Wiley & Sons Ltd on behalf of European Academy of Dermatology and Venereology. https://creativecommons.org/licenses/by/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.
spellingShingle Short Reports
Weltler, Patrick
Rappersberger, Klemens
Filzmoser, Peter
Vujic, Igor
The impact of the COVID‐19 pandemic on melanoma diagnoses
title The impact of the COVID‐19 pandemic on melanoma diagnoses
title_full The impact of the COVID‐19 pandemic on melanoma diagnoses
title_fullStr The impact of the COVID‐19 pandemic on melanoma diagnoses
title_full_unstemmed The impact of the COVID‐19 pandemic on melanoma diagnoses
title_short The impact of the COVID‐19 pandemic on melanoma diagnoses
title_sort impact of the covid‐19 pandemic on melanoma diagnoses
topic Short Reports
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9088572/
https://www.ncbi.nlm.nih.gov/pubmed/37829553
http://dx.doi.org/10.1002/jvc2.15
work_keys_str_mv AT weltlerpatrick theimpactofthecovid19pandemiconmelanomadiagnoses
AT rappersbergerklemens theimpactofthecovid19pandemiconmelanomadiagnoses
AT filzmoserpeter theimpactofthecovid19pandemiconmelanomadiagnoses
AT vujicigor theimpactofthecovid19pandemiconmelanomadiagnoses
AT weltlerpatrick impactofthecovid19pandemiconmelanomadiagnoses
AT rappersbergerklemens impactofthecovid19pandemiconmelanomadiagnoses
AT filzmoserpeter impactofthecovid19pandemiconmelanomadiagnoses
AT vujicigor impactofthecovid19pandemiconmelanomadiagnoses